GSK (NYSE:GSK) (LON:GSK) said on Monday that the U.S. Food and Drug Administration has accepted its priority review ...

British drugmaker GSK said on Monday that the U.S. Food and Drug Administration has accepted its application for priority ...

A new study shows that while RSV mostly affects younger kids, the often-overlooked human metapneumovirus also hospitalizes ...

GSK (NYSE:GSK) announced Monday that the U.S. Food and Drug Administration has accepted its priority review application for ...

The "2025 Healthy Aging Korea" forum, which marks its second anniversary this year, was held at the British Embassy in ...

Respiratory syncytial virus vaccine uptake was low among older veterans, with disparities observed across demographic and social risk factors.

RSV vaccine recommended for adults 60+ with health issues, infants under 19 months, and all healthy adults 75+. Helps prevent ...

GSK and CureVac will together receive $740 million, as well as royalties on sales of COVID-19 vaccines in the US ...

Palivizumab injection (Synagis), an RSV prevention therapy for children, is being discontinued and will no longer be available as of December 31, 2025.

RSV hospitalization was associated with increased risk for new CVEs and worsening of preexisting cardiovascular conditions.

According to the latest study from BCC Research, "Global Markets for Infectious Disease Treatments" is expected to grow from ...